Introduction
Lymphomas are malignant hematologic tumors associated with malignancy of certain immune cells produced by proliferation and differentiation of lymphocytes, and are classified into two categories according to histopathologic changes: non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL). They can be divided into B-cell, T-cell and NK-cell lymphomas, in accordance to the origin of the lymphocytes. 2016 World Health Organization (WHO) reclassify of hematopoietic and lymphoid tissue tumors 1, lymphomas are mostly B-cell in origin. Malignant lymphoma is becoming more frequent in China, which is comparable to leukemia, and present remedy alternatives have no longer improved outcomes.
There is presently no therapy for B cell lymphoma; it can only be slowed or controlled. The stunning effects of gene editing in duchenne muscular dystrophy (DMD)2 and sickle cellphone anemia (SCD)3 have researchers interested. Jeffrey C Miller et al 4 developed zinc finger nucleases (ZFNs) to target genes, and with the rapid development of science and technology, transcription activator-like effector nucleases (TALENs)5,6 and clustered regularly interspaced short palindromic repeats (CRISPR) Cas9 7,8 have emerged one after another, with CRISPR/Cas9 being the most thoroughly studied and most commonly used.